Relevance of CYP2D6 variability in first-episode schizophrenia
patients treated with risperidone

J 2012

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ et. al.

Basic information

Original name

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone

Authors

BARTEČEK, Richard (203 Czech Republic, belonging to the institution), Jan JUŘICA (203 Czech Republic, guarantor, belonging to the institution), Jana ZRUSTOVA (203 Czech Republic), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution), Eva PINDUROVÁ (203 Czech Republic) and Alexandra ŽOURKOVÁ (203 Czech Republic)

Edition

Neuroendocrinology Letters, Stockholm, Maghira and Maas Publications, 2012, 0172-780X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Sweden

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 0.932

RIV identification code

RIV/00216224:14740/12:00060575

Organization unit

Central European Institute of Technology

UT WoS

000305037700020

Keywords in English

Cytochrome P-450; CYP2D6; pharmacogenetics; CYP2D6 analysis; schizophrenia; risperidone

Abstract

V originále

OBJECTIVE: The objective of this prospective, naturalistic study, conducted in first-episode psychosis patients from a Central-European population, was to assess the utility of Cytochrome P-450 2D6 (CYP2D6) genotype testing under normal clinical setting. METHODS: A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study. These patients underwent sequentiation of the CYP2D6 gene and evaluations of symptoms and severity of adverse effects using the PANSS and UKU scales, respectively. Doses of antipsychotics and other co-medication were monitored as well. In statistical analysis, Fisher's exact test was used to compare ratios and the Wilcoxon rank-sum test was used in the comparison of continual variables. RESULTS: PM patients showed a significantly lower reduction in psychotic symptoms and a greater severity of psychotic symptoms following risperidone treatment and higher doses of antipsychotics not metabolized by CYP2D6, which were used as co-medication. CONCLUSIONS: Based on these results, patients with the PM genotype experiencing first-episode schizophrenia don't appear to be optimal recipients of risperidone treatment. However, as the main limitation of this study was the relatively small sample-size, replication with a larger scale study is needed to confirm these findings.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

NS9676, research and development project

Name: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Investor: Ministry of Health of the CR

Citovat

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ and Alexandra ŽOURKOVÁ. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuroendocrinology Letters. Stockholm: Maghira and Maas Publications, 2012, vol. 33, No 2, p. 236-244. ISSN 0172-780X.

@article{989157,
   author = {Barteček, Richard and Juřica, Jan and Zrustova, Jana and Kašpárek, Tomáš and Pindurová, Eva and Žourková, Alexandra},
   article_location = {Stockholm},
   article_number = {2},
   keywords = {Cytochrome P-450; CYP2D6; pharmacogenetics; CYP2D6 analysis; schizophrenia; risperidone},
   language = {eng},
   issn = {0172-780X},
   journal = {Neuroendocrinology Letters},
   title = {Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone},
   url = {http://www.ncbi.nlm.nih.gov/pubmed/22592207},
   volume = {33},
   year = {2012}
}

TY  - JOUR
ID  - 989157
AU  - Barteček, Richard - Juřica, Jan - Zrustova, Jana - Kašpárek, Tomáš - Pindurová, Eva - Žourková, Alexandra
PY  - 2012
TI  - Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone
JF  - Neuroendocrinology Letters
VL  - 33
IS  - 2
SP  - 236-244
EP  - 236-244
PB  - Maghira and Maas Publications
SN  - 0172780X
KW  - Cytochrome P-450
KW  - CYP2D6
KW  - pharmacogenetics
KW  - CYP2D6 analysis
KW  - schizophrenia
KW  - risperidone
UR  - http://www.ncbi.nlm.nih.gov/pubmed/22592207
L2  - http://www.ncbi.nlm.nih.gov/pubmed/22592207
N2  - OBJECTIVE: The objective of this prospective, naturalistic study, conducted in first-episode psychosis patients from a Central-European population, was to assess the utility of Cytochrome P-450 2D6 (CYP2D6) genotype testing under normal clinical setting. METHODS: A total of 35 patients diagnosed for the first time with schizophrenia or acute schizophrenia-like psychotic disorder and treated with risperidone were enrolled in the study. These patients underwent sequentiation of the CYP2D6 gene and evaluations of symptoms and severity of adverse effects using the PANSS and UKU scales, respectively. Doses of antipsychotics and other co-medication were monitored as well. In statistical analysis, Fisher's exact test was used to compare ratios and the Wilcoxon rank-sum test was used in the comparison of continual variables. RESULTS: PM patients showed a significantly lower reduction in psychotic symptoms and a greater severity of psychotic symptoms following risperidone treatment and higher doses of antipsychotics not metabolized by CYP2D6, which were used as co-medication. CONCLUSIONS: Based on these results, patients with the PM genotype experiencing first-episode schizophrenia don't appear to be optimal recipients of risperidone treatment. However, as the main limitation of this study was the relatively small sample-size, replication with a larger scale study is needed to confirm these findings.
ER  -

BARTEČEK, Richard, Jan JUŘICA, Jana ZRUSTOVA, Tomáš KAŠPÁREK, Eva PINDUROVÁ and Alexandra ŽOURKOVÁ. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. \textit{Neuroendocrinology Letters}. Stockholm: Maghira and Maas Publications, 2012, vol.~33, No~2, p.~236-244. ISSN~0172-780X.

Detailed Information on Publication Record